Day: December 8, 2023

The U.S. Commerce Department and the National Oceanic and Atmospheric Administration (NOAA) announced Friday $1 million in funding to improve the collection of Arctic climate data.

In a statement, U.S. Commerce Secretary Gina Raimondo said the U.S. Arctic region — which consists of the state of Alaska — is warming faster than any region in the United States and demands immediate action.

She said the new funding — part of the 2022 Inflation Reduction Act, which included money for clean energy development — will provide “data and tools that can build climate resilience and strengthen our economy and national security.”

The $1 million in funding will be used to solicit grant ideas from institutions of higher education, other nonprofits or commercial organizations to help improve climate and data collection, with a focus on Alaskan communities.

In the same statement, NOAA Administrator Rick Spinrad said, the call for grant proposals is designed to both gather data and help Alaskan rural and Indigenous communities.

“Providing communities with environmental information that allows them to make informed decisions in the face of a changing climate is the foundation of creating a more climate resilient nation,” he said.

The most recent NOAA National Climate Assessment indicates Alaska is warming at a rate that is two to three times faster than the lower 48 states, and the Arctic as a whole is warming nearly four times faster than the rest of the global average.
…

In a letter leaked to news organizations this week, OPEC Secretary-General Haitham Al Ghais urged member nations to reject any agreement from the U.N. climate summit targeting fossil fuels rather than emissions.

In the letter dated Wednesday referencing a draft agreement on climate change action at the 28th U.N. climate conference — known as COP28 — in Dubai, the OPEC leader said, “It seems that the undue and disproportionate pressure against fossil fuels may reach a tipping point with irreversible consequences.”

The letter goes on to say, “I … respectfully urge all esteemed OPEC Member Countries and Non-OPEC Countries participating in the CoC and their distinguished delegations in the COP 28 negotiations to proactively reject any text or formula that targets energy i.e. fossil fuels rather than emissions.”

The contents of the letter were reported Friday by multiple news organizations, including Agence France-Presse, Reuters and Bloomburg, which verified the letter’s authenticity. OPEC declined when asked to comment.

The reports come as negotiations among 197 countries on a final climate summit agreement are underway ahead of a deadline Tuesday, when the conference is scheduled to end.

Fossil fuels — oil, coal and natural gas — have been a focus of the discussions since COP28 opened last week, with U.N. Secretary-General Antonio Guterres calling for an end to their use.

At least 80 countries have called for a COP28 deal that calls for an eventual end to fossil fuel use, as scientists urge ambitious action to avert the worst impacts of climate change.

The focus is on meeting the goal of the 2015 Paris climate agreement: keeping global temperature increase this century less than 1.5 degrees Celsius above pre-industrial levels.

At Friday’s climate summit plenary session, COP28 President Sultan Al Jaber, from OPEC member nation and summit host United Arab Emirates, said, once again, that a shift away from fossil fuels is “inevitable” and “essential.” He added, though, that any energy transition “must be orderly and responsible.”

Some information for this report came from The Associated Press, Reuters and Agence France-Presse.
…

The U.S. Food and Drug Administration (FDA) on Friday approved a pair of gene therapies for sickle cell disease, including the first treatment based on the breakthrough CRISPR gene editing technology. 

The agency approved Lyfgenia from bluebird bio, and a separate treatment called Casgevy by partners Vertex Pharmaceuticals and CRISPR Therapeutics. 

Both the therapies were approved for people aged 12 years and older. 

The Vertex/CRISPR gene therapy uses the breakthrough gene editing technology that won its inventors the Nobel Prize in 2020. 

Sickle cell disease is a painful, inherited blood disorder that can be debilitating and lead to premature death. It affects an estimated 100,000 people in the United States, most of whom are Black. 

In sickle cell disease, the body makes flawed, sickle-shaped hemoglobin, impairing the ability of red blood cells to properly carry oxygen to the body’s tissues. 

The sickle cells tend to stick together and can block small blood vessels, causing intense pain. It also can lead to strokes and organ failure. 

U.S.-listed shares of CRISPR therapeutics were up 1.6%, while Vertex Pharmaceuticals stock was down 1.4%. Shares of bluebird bio were halted for trading ahead of the news. 

Makers of both the therapies have pitched them as one-time treatments, but data on how long their effect lasts is limited. The only longer-term treatment for sickle cell disease is a bone marrow transplant. 

“I actually am very reticent to call them a cure. I prefer to call them a transformative therapy because patients will still have sickle cell disease on the other side of gene therapy,” said Dr Sharl Azar, medical director of the Comprehensive Sickle Cell Disease Treatment Center at Massachusetts General Hospital. 

Bluebird bio’s sickle cell therapy is designed to work by inserting modified genes into the body through disabled viruses to help the patient’s red blood cells produce normal hemoglobin. 

For Vertex’s therapy, patients must have stem cells harvested from their bone marrow. The cells are then sent to manufacturing facilities where they are edited using CRISPR/Cas9 technology. Once the cells are incubated, they are infused back into the patient during a month-long hospital stay. 

Both gene therapies can take several months and involve high-dose chemotherapy, but this has potential risks of infertility. 

“Not everybody who undergoes chemotherapy will end up having infertility, but the majority of them will,” said Dr Azar.  

While the risk can be managed by fertility preservation methods like freezing eggs and sperm banking, this is only covered by insurance for cancer patients who undergo chemotherapy and not those receiving gene therapy, said Dr. Azar. 

He said the out-of-pocket expense on it can be as high as $40,000. 

FDA staff in documents released ahead of an October meeting of a panel of independent experts on Vertex’s therapy had also flagged concerns of unintended genomic alterations from the treatment. 

The company plans to assess potential long-term safety risks through a 15-year follow-up study after approval. 

Vertex’s CRISPR therapy is also under an FDA review for another blood disease, transfusion-dependent beta thalassemia, with a decision expected by March 30. 
…

Black people make up about 38% of Mississippi’s population, but a new study shows that Black women were four times more likely to die of causes directly related to pregnancy than white women in the state in 2020.

“It is imperative that this racial inequity is not only recognized, but that concerted efforts are made at the institutional, community, and state levels to reduce these disparate outcomes,” wrote Dr. Michelle Owens and Dr. Courtney Mitchell, leaders of the Maternal Mortality Review Committee that conducted the study.

The Mississippi State Department of Health published the findings Wednesday.

The committee said 80% of pregnancy-related deaths in Mississippi between 2016 and 2020 were considered preventable, and cardiovascular disease and hypertension remain top contributors to maternal mortality.

Women need comprehensive primary care before, during and after pregnancy, but many people live in areas where health care services are scarce, Owens and Mitchell wrote.

“A substantial portion of this care is being shouldered by smaller hospitals with limited resources, many of whom are facing possible closure and limiting or discontinuing the provision of obstetrical services, further increasing the burdens borne by the individuals and their communities,” they wrote.

The Maternal Mortality Review Committee was formed in 2017, and its members include physicians, nurses, public health experts and others who work in health care.

The committee found that from 2016 to 2020, Mississippi’s pregnancy-related mortality rate was 35.2 deaths per 100,000 live births. The study did not provide a comparable five-year number for the U.S. but said the national rate was 20.1 deaths per 100,000 live births in 2019 and 32.9 deaths per 100,000 live births in 2020.

Mississippi has long been one of the poorest states in the U.S., with some of the highest rates of obesity and heart disease.

A state health department program called Healthy Moms, Healthy Babies offers care management and home visits for pregnant women and for infants who are at risk of having health problems.

“Losing one mother is too many,” Dr. Daniel Edney, the state health officer, said in a news release about the maternal mortality study.

The committee recommended that Mississippi leaders expand Medicaid to people who work in lower-wage jobs that don’t provide private health insurance — a policy proposal that Republican Gov. Tate Reeves has long opposed.

Earlier this year, Reeves signed a law allowing postpartum Medicaid coverage for a full year, up from two months.

Medicaid expansion is optional under the health care overhaul that then-President Barack Obama signed into law in 2010, and Mississippi is one of 10 states that have not taken the option. The non-expansion states have Republican governors, Republican-controlled Legislatures or both.

“Medicaid expansion should be incorporated for rural hospitals to remain open and include access to telehealth services,” the Maternal Mortality Review Committee leaders wrote. “There is a need for rural healthcare facilities to provide higher levels of critical care, recruit and retain adequate providers, and have access to life saving equipment, especially in the most vulnerable areas of the state.”

The study examined deaths that occurred during or within one year after pregnancy. It defined pregnancy-related deaths as those “initiated by pregnancy, or the aggravation of an unrelated condition by the physiologic effects of pregnancy” and pregnancy-associated deaths as those “from a cause that is not related to pregnancy.”

Pregnancy-related deaths during the five years included 17 homicides and four suicides, plus 26 instances of substance abuse disorder contributing to the maternal death and 30 instances of mental health conditions other than substance abuse disorder contributing to a death.

The study also said obesity contributed to 32 maternal deaths and discrimination contributed to 22. It noted that some pregnancy-related deaths could have more than one contributing factor.

The committee recommended that health care providers develop procedures and training to address maternal patients with severe complaints for the same health concern, including training to eliminate bias or discrimination.
…

Environmental watchdogs accused a Mexico-based startup Thursday of violating international trade law by selling a health supplement made from endangered totoaba fish to several countries including the U.S. and China.

Advocates told The Associated Press they also have concerns that the company, The Blue Formula, could be selling fish that is illegally caught in the wild.

The product, which the company describes as “nature’s best kept secret,” is a small sachet of powder containing collagen taken from the fish that is designed to be mixed into a drink.

Under the Convention on International Trade in Endangered Species of Wild Fauna and Flora, to which Mexico and the U.S. are both signatories, any export for sale of totoaba fish is illegal, unless bred in captivity with a particular permit. As a listed protected species, commercial import is also illegal under U.S. trade law.

The environmental watchdog group Cetacean Action Treasury first cited the company in November. Then on Thursday, a coalition of environmental charities — The Center for Biological Diversity, National Resources Defense Council and Animal Welfare Institute — filed a written complaint to CITES.

The Blue Formula did not immediately respond to an AP request for comment.

The company claims on its website to operate “100%” sustainably by sourcing fish from Cygnus Ocean, a farm which has a permit to breed totoaba, and using a portion of their profits to release some farmed fish back into the wild.

However, Cygnus Ocean does not have a permit for commercial export of their farmed fish, according to the environmental groups. The farm also did not immediately respond to a request from the AP for comment.

While the ecological impact of breeding totoaba in captivity is much smaller relative to wild fishing, advocates like Alejandro Olivera, the Center for Biological Diversity’s Mexico representative, fear the company and farm could be used as a front.

“There is no good enforcement of the traceability of totoaba in Mexico,” said Olivera, “so it could be easily used to launder wild totoaba.”

Gillnet fishing for wild totoaba is illegal and one of the leading killers of critically endangered vaquita porpoise, of which recent surveys suggest less than a dozen may exist in the wild.

Gillnetting is driven by the exorbitant price for totoaba bladders in China, where they are sold as a delicacy for as much as gold. The Blue Formula’s supplement costs just under $100 for 200 grams.

In October U.S. Customs and Border Protection seized over $1 million worth of totoaba bladders in Arizona, hidden in a shipment of frozen fish. Roughly as much again was seized in Hong Kong the same month, in transit from Mexico to Thailand.
…